NCT00641199

Probiotics for Prevention of Antibiotic-associated Diarrhea

The Effect of Jarro-Dophilus EPS Probiotics on the Prevention of Diarrhea, Quality of Life and Symptoms in Adults Receiving Antibiotic Therapy.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 204 (estimated)
• Sponsor: University of Saskatchewan · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate if ingestion of a probiotic formula (Jarrow-Dophilus EPS)reduces incidence of diarrhea and improves the quality of life of patients receiving antibiotic therapy.

Detailed description

A common complication of antibiotic use is antibiotic-induced diarrhea (AAD). AAD is the result of disrupted microflora, occurring two to eight weeks after antibiotic use. Probiotic supplementation may rebalance the intestinal flora, thus reducing the incidence of diarrhea, improving quality of life and reducing symptoms associated with antibiotic administration. The proposed study will be a prospective, randomized, double blind, placebo-controlled trial that will assess the efficacy of the Jarro-Dophilus EPS probiotics formula for the prevention of AAD. In addition,a subgroup of participants will be requested to provide one fecal sample at the initiation of the study and one sample in the last three days of probiotic (or placebo) treatment. The samples will undergo microbial analysis for routine C \& S(Salmonella, Shigella, Campylobacter, Ecoli 0157, Yersinia), VRE, Yeast, Fungus culture (moulds) and C. difficile toxin.

Conditions

• Antibiotic-Associated Diarrhea

Interventions

Type	Name	Description
OTHER	Jarro-Dophilus EPS probiotics	Jarro-Dophilus EPS product 2 capsules twice daily. 4.4 billion live bacteria per capsule.

Timeline

• Start date: 2008-03-01
• Primary completion: 2009-09-01
• Completion: 2009-09-01
• First posted: 2008-03-24
• Last updated: 2010-01-15

Locations

1 site across 1 country: Canada